犬の関節炎市場：製品タイプ、投与経路、エンドユーザー、治療タイプ別-2025-2030年の世界予測

犬の関節炎市場は、2023年に18億1,000万米ドルと評価され、2024年には19億2,000万米ドルに達すると予測され、CAGR 7.88％で成長し、2030年には30億8,000万米ドルに達すると予測されています。

犬の関節炎、退行性関節疾患は、主に犬の軟骨に影響を与え、痛み、こわばり、運動障害をもたらします。ペット飼育の増加や高齢犬の増加などの要因により、犬の関節炎の有病率が上昇するにつれて、犬の関節炎の治療と管理の市場は大きく拡大しています。犬における効果的な関節炎治療の必要性は否定できず、その主な理由は、ペットの福祉に対する理解の向上と、ペットヘルスケアの人間化への傾向の高まりによるものです。関節炎管理のためのアプリケーションは、非ステロイド性抗炎症薬（NSAIDs）や疾患修飾性変形性関節症治療薬（DMOADs）のような医薬品介入から、理学療法、鍼治療、栄養補助食品のような非医薬品療法まで多岐にわたります。最終用途には、動物病院、ペット病院、さらにはペットの生活の質を維持したいと願う飼い主が提供する家庭内ケアソリューションが含まれます。主な成長要因としては、より新しく効果的な治療を提供する獣医学の進歩と、関節炎の症状や治療法に関する飼い主の意識の高まりが挙げられます。一方、未開拓の機会は、革新的で低侵襲な治療技術の開発と、ペットのためのオーガニックで自然な健康ソリューションを求める消費者の嗜好に沿った、自然またはホリスティックな治療オプションの普及に存在します。とはいえ、高度な治療に伴う高額な費用、ペットの保険適用不足、新興国市場での認識不足といった課題によって、市場の成長は抑制されています。技術革新が必要な分野には、早期発見のための診断ツールの強化や、個々の遺伝子プロファイルに基づく個別化治療計画などがあります。市場力学の性質はダイナミックであり、獣医学の急速な進歩や消費者の情報収集の活発化を特徴としているため、企業は治療の有効性だけでなく、消費者の啓蒙やアクセシビリティの拡大にも注力し、成長を促進する必要があります。

市場力学：急速に進化する犬の関節炎市場の主要市場インサイトを公開

犬の関節炎市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ペットの高齢化とライフスタイルによる世界の犬人口における関節炎の有病率の増加
  • 犬の関節炎を効果的に管理するための獣医学および治療における技術革新
  • 犬の健康とウェルネスに対する飼い主の意識の高まりと支出意欲の向上
  • 犬の関節炎の早期発見と治療につながる診断技術の進歩
• 市場抑制要因
  • 犬の関節炎の症例に適切に対処するための専門獣医の数の不足
  • 犬の関節炎の新規治療法の承認と利用可能性に影響する規制上の課題
• 市場機会
  • ホリスティックおよび統合医療的アプローチを提供する犬の関節炎専門治療センター
  • 関節炎を患う犬のための関節用サプリメントや痛み止め薬の定期購入型配送
  • 犬の関節炎症状の継続的モニタリングと管理のためのウェアラブル技術
• 市場の課題
  • 動物病院での治療や関節炎治療にかかる高額な費用により、市場へのアクセスが低下しています。
  • 早期徴候と予防ケアに関する飼い主の認識と教育の欠如犬の関節炎

ポーターの5つの力：犬の関節炎市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：犬の関節炎市場における外部からの影響の把握

外部マクロ環境要因は、犬の関節炎市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析犬の関節炎市場における競合情勢の把握

犬の関節炎市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス犬の関節炎市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、犬の関節炎市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨犬の関節炎市場における成功への道筋を描く

犬の関節炎市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ペットの高齢化とライフスタイルの変化により、世界中の犬の関節炎の罹患率が上昇している
    • 獣医学における革新と犬の関節炎を効果的に管理するための治療法
    • 犬の健康とウェルネスに対する意識と飼い主の支出意欲の高まり
    • 犬の関節炎の早期発見と治療につながる診断技術の進歩
  • 抑制要因
    • 犬の関節炎のケースに適切に対処するには専門の獣医専門家の数が不足している
    • 犬の関節炎の新規治療法の承認と利用可能性に影響を与える規制上の課題
  • 機会
    • 総合的かつ総合的な医療アプローチを提供する専門犬の関節炎治療センター
    • 関節炎の犬のための関節サプリメントと鎮痛薬の定期便
    • 犬の関節炎症状を継続的に監視・管理するためのウェアラブル技術
  • 課題
    • 獣医治療と関節炎治療にかかる費用が高く、市場へのアクセスが制限される
    • ペットの飼い主の間で、犬の関節炎の初期兆候と予防ケアに関する認識と教育が不足している
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTLE分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 犬の関節炎市場：製品タイプ別

• 補助器具と関節サポート
  • ブレース
  • ハーネス
  • その他の補助器具
• 変形性関節症治療薬（DMOAD）
  • 構造修飾DMOAD
  • 症状のあるDMOAD
• 非ステロイド性抗炎症薬（NSAID）
  • 市販のNSAID
  • 処方NSAID
• 疼痛管理薬
  • オピオイド
  • その他の疼痛管理薬
  • ステロイド
• 外科的治療
  • 関節鏡手術
  • 関節置換手術
  • その他の外科的治療

第7章 犬の関節炎市場：投与経路別

• 注射可能
• オーラル
• 話題

第8章 犬の関節炎市場：エンドユーザー別

• オンライン薬局
• 小売薬局
• 動物病院と診療所

第9章 犬の関節炎市場治療の種類別

• 薬物療法
• 理学療法
  • 鍼
  • ハイドロセラピー
  • レーザー治療
  • その他の理学療法
• 外科的治療

第10章 南北アメリカの犬の関節炎市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の犬の関節炎市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの犬の関節炎市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• 1. Bayer AG
• 2. Boehringer Ingelheim International GmbH
• 3. Ceva Sante Animale
• 4. Dechra Pharmaceuticals PLC
• 5. Elanco Animal Health Incorporated
• 6. Merck Animal Health
• 7. Nutramax Laboratories, Inc.
• 8. Vetoquinol S.A.
• 9. Virbac
• 10. Zoetis Inc.

LIST OF FIGURES

• FIGURE 1. CANINE ARTHRITIS MARKET RESEARCH PROCESS
• FIGURE 2. CANINE ARTHRITIS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. CANINE ARTHRITIS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. CANINE ARTHRITIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. CANINE ARTHRITIS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL CANINE ARTHRITIS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. CANINE ARTHRITIS MARKET DYNAMICS
• TABLE 7. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY BRACES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HARNESSES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OTHER ASSISTIVE DEVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY STRUCTURE-MODIFYING DMOADS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SYMPTOMATIC DMOADS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OVER-THE-COUNTER NSAIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PRESCRIPTION NSAIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OTHER PAIN MANAGEMENT DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY STEROIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ARTHROSCOPIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY JOINT REPLACEMENT SURGERY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OTHER SURGICAL TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY VETERINARY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY HYDROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY LASER THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY OTHER PHYSICAL THERAPIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 47. GLOBAL CANINE ARTHRITIS MARKET SIZE, BY SURGICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 69. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 79. CANADA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 80. CANADA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 81. CANADA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 82. CANADA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 83. CANADA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 84. CANADA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 85. CANADA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. CANADA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 87. CANADA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. CANADA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 89. MEXICO CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 90. MEXICO CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 91. MEXICO CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 92. MEXICO CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 93. MEXICO CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 99. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 100. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 101. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 102. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES CANINE ARTHRITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 110. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 112. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 113. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 114. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 121. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 122. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 123. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 124. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 125. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 126. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 131. CHINA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 132. CHINA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 133. CHINA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 134. CHINA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 135. CHINA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 136. CHINA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 137. CHINA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 138. CHINA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 139. CHINA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. CHINA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 141. INDIA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 142. INDIA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 143. INDIA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 144. INDIA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 145. INDIA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 146. INDIA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 147. INDIA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 148. INDIA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. INDIA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. INDIA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 151. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 152. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 153. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 154. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 155. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 156. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 157. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 158. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 159. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 161. JAPAN CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 162. JAPAN CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 163. JAPAN CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 164. JAPAN CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 165. JAPAN CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 166. JAPAN CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 167. JAPAN CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 168. JAPAN CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 169. JAPAN CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 170. JAPAN CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 171. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 173. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 174. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 175. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 176. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 177. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 178. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 179. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 180. MALAYSIA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 181. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 182. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 183. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 184. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 185. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 186. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 187. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 188. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 189. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 190. PHILIPPINES CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 191. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 192. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 193. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 194. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 195. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 196. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 197. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 198. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 199. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 200. SINGAPORE CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 204. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 205. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 206. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 207. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 208. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 209. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SOUTH KOREA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 211. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 212. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 213. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 214. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 215. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 216. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 217. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 218. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 219. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 220. TAIWAN CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 221. THAILAND CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 222. THAILAND CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 223. THAILAND CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 224. THAILAND CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 225. THAILAND CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 226. THAILAND CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 227. THAILAND CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 228. THAILAND CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 229. THAILAND CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 230. THAILAND CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 231. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 232. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 233. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 234. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 235. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 236. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 237. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 238. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 239. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 240. VIETNAM CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 241. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 242. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 243. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 244. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 245. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 246. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 247. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 248. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 249. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 250. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 251. EUROPE, MIDDLE EAST & AFRICA CANINE ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 252. DENMARK CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 253. DENMARK CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 254. DENMARK CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 255. DENMARK CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 256. DENMARK CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 257. DENMARK CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 258. DENMARK CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 259. DENMARK CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 260. DENMARK CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 261. DENMARK CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 262. EGYPT CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 263. EGYPT CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 264. EGYPT CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 265. EGYPT CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 266. EGYPT CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 267. EGYPT CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 268. EGYPT CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 269. EGYPT CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 270. EGYPT CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 271. EGYPT CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 272. FINLAND CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 273. FINLAND CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 274. FINLAND CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 275. FINLAND CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 276. FINLAND CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 277. FINLAND CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 278. FINLAND CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 279. FINLAND CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 280. FINLAND CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 281. FINLAND CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 282. FRANCE CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 283. FRANCE CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 284. FRANCE CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 285. FRANCE CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 286. FRANCE CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 287. FRANCE CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 288. FRANCE CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 289. FRANCE CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 290. FRANCE CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 291. FRANCE CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 292. GERMANY CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 293. GERMANY CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 294. GERMANY CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 295. GERMANY CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 296. GERMANY CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 297. GERMANY CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 298. GERMANY CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 299. GERMANY CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 300. GERMANY CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 301. GERMANY CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 302. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 303. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 304. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 305. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 306. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 307. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 308. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 309. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 310. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
• TABLE 311. ISRAEL CANINE ARTHRITIS MARKET SIZE, BY PHYSICAL THERAPY, 2018-2030 (USD MILLION)
• TABLE 312. ITALY CANINE ARTHRITIS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 313. ITALY CANINE ARTHRITIS MARKET SIZE, BY ASSISTIVE DEVICES AND JOINT SUPPORT, 2018-2030 (USD MILLION)
• TABLE 314. ITALY CANINE ARTHRITIS MARKET SIZE, BY DISEASE-MODIFYING OSTEOARTHRITIS DRUGS (DMOADS), 2018-2030 (USD MILLION)
• TABLE 315. ITALY CANINE ARTHRITIS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), 2018-2030 (USD MILLION)
• TABLE 316. ITALY CANINE ARTHRITIS MARKET SIZE, BY PAIN MANAGEMENT DRUGS, 2018-2030 (USD MILLION)
• TABLE 317. ITALY CANINE ARTHRITIS MARKET SIZE, BY SURGICAL TREATMENTS, 2018-2030 (USD MILLION)
• TABLE 318. ITALY CANINE ARTHRITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 319. ITALY CANINE ARTHRITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 320. ITALY CANINE ARTHRITIS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)

The Canine Arthritis Market was valued at USD 1.81 billion in 2023, expected to reach USD 1.92 billion in 2024, and is projected to grow at a CAGR of 7.88%, to USD 3.08 billion by 2030.

Canine arthritis, a degenerative joint disease, primarily affects the cartilage in dogs, leading to pain, stiffness, and impaired movement. As the prevalence of arthritis in dogs rises, driven by factors such as increasing pet ownership and a growing population of aged dogs, the market for canine arthritis treatment and management is expanding significantly. The necessity for effective arthritis treatments in dogs is undeniable, primarily due to the enhanced understanding of pet welfare and the increasing trend towards humanizing pet healthcare. Applications for arthritis management range from pharmaceutical interventions, such as non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying osteoarthritis drugs (DMOADs), to non-pharmaceutical therapies like physiotherapy, acupuncture, and dietary supplements. The end-use scope involves veterinary clinics, pet hospitals, and even in-home care solutions provided by pet owners who wish to maintain their pets' quality of life. Key growth influencers are advancements in veterinary medicine that provide newer, more effective treatments, and heightened awareness among pet owners about arthritis symptoms and treatment options. Meanwhile, untapped opportunities reside in the development of innovative, minimally invasive treatment techniques and the proliferation of natural or holistic treatment options, aligning with consumer preferences for organic and natural health solutions for their pets. Nonetheless, the market's growth is curtailed by challenges such as high costs associated with advanced treatments, lack of insurance coverage for pets, and insufficient awareness in developing regions. Areas ripe for innovation include enhanced diagnostic tools for early detection and personalized treatment plans based on individual genetic profiles. The nature of the canine arthritis market is dynamic, characterized by rapid advancements in veterinary science and an increasingly informed consumer base, suggesting that businesses should focus not just on treatment efficacy but also on educating consumers and broadening accessibility to drive growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Canine Arthritis Market

The Canine Arthritis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increasing prevalence of arthritis among the global canine population due to aging pets and lifestyle
  • Innovations in veterinary medicine and treatments for managing canine arthritis effectively
  • Growing awareness and pet owner's willingness to spend on canine health and wellness
  • Advancements in diagnostic techniques leading to early detection and treatment of arthritis in dogs
• Market Restraints
  • Insufficient number of specialized veterinary professionals to adequately address canine arthritis cases
  • Regulatory challenges affecting the approval and availability of novel treatments for canine arthritis
• Market Opportunities
  • Specialized canine arthritis treatment centers offering holistic and integrative medical approaches
  • Subscription-based delivery of joint supplements and pain relief medications for arthritic dogs
  • Wearable technology for continuous monitoring and management of arthritis symptoms in dogs
• Market Challenges
  • High costs associated with veterinary care and arthritis treatments leading to reduced market accessibility
  • Lack of awareness and education among pet owners about early signs and preventive care for canine arthritis

Porter's Five Forces: A Strategic Tool for Navigating the Canine Arthritis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Canine Arthritis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Canine Arthritis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Canine Arthritis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Canine Arthritis Market

A detailed market share analysis in the Canine Arthritis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Canine Arthritis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Canine Arthritis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Canine Arthritis Market

A strategic analysis of the Canine Arthritis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Canine Arthritis Market, highlighting leading vendors and their innovative profiles. These include Bayer AG, Boehringer Ingelheim International GmbH, Ceva Sante Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health Incorporated, Merck Animal Health, Nutramax Laboratories, Inc., Vetoquinol S.A., Virbac, and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Canine Arthritis Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product Type, market is studied across Assistive Devices and Joint Support, Disease-Modifying Osteoarthritis Drugs (DMOADs), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Pain Management Drugs, and Surgical Treatments. The Assistive Devices and Joint Support is further studied across Braces, Harnesses, and Other Assistive Devices. The Disease-Modifying Osteoarthritis Drugs (DMOADs) is further studied across Structure-Modifying DMOADs and Symptomatic DMOADs. The Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is further studied across Over-the-Counter NSAIDs and Prescription NSAIDs. The Pain Management Drugs is further studied across Opioids, Other Pain Management Drugs, and Steroids. The Surgical Treatments is further studied across Arthroscopic Surgery, Joint Replacement Surgery, and Other Surgical Treatments.
• Based on Route of Administration, market is studied across Injectable, Oral, and Topical.
• Based on End User, market is studied across Online Pharmacies, Retail Pharmacies, and Veterinary Hospitals and Clinics.
• Based on Therapy Type, market is studied across Drug Therapy, Physical Therapy, and Surgical Therapy. The Physical Therapy is further studied across Acupuncture, Hydrotherapy, Laser Therapy, and Other Physical Therapies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing prevalence of arthritis among the global canine population due to aging pets and lifestyle
    • 5.1.1.2. Innovations in veterinary medicine and treatments for managing canine arthritis effectively
    • 5.1.1.3. Growing awareness and pet owner's willingness to spend on canine health and wellness
    • 5.1.1.4. Advancements in diagnostic techniques leading to early detection and treatment of arthritis in dogs
  • 5.1.2. Restraints
    • 5.1.2.1. Insufficient number of specialized veterinary professionals to adequately address canine arthritis cases
    • 5.1.2.2. Regulatory challenges affecting the approval and availability of novel treatments for canine arthritis
  • 5.1.3. Opportunities
    • 5.1.3.1. Specialized canine arthritis treatment centers offering holistic and integrative medical approaches
    • 5.1.3.2. Subscription-based delivery of joint supplements and pain relief medications for arthritic dogs
    • 5.1.3.3. Wearable technology for continuous monitoring and management of arthritis symptoms in dogs
  • 5.1.4. Challenges
    • 5.1.4.1. High costs associated with veterinary care and arthritis treatments leading to reduced market accessibility
    • 5.1.4.2. Lack of awareness and education among pet owners about early signs and preventive care for canine arthritis
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Canine Arthritis Market, by Product Type

• 6.1. Introduction
• 6.2. Assistive Devices and Joint Support
  • 6.2.1. Braces
  • 6.2.2. Harnesses
  • 6.2.3. Other Assistive Devices
• 6.3. Disease-Modifying Osteoarthritis Drugs (DMOADs)
  • 6.3.1. Structure-Modifying DMOADs
  • 6.3.2. Symptomatic DMOADs
• 6.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.4.1. Over-the-Counter NSAIDs
  • 6.4.2. Prescription NSAIDs
• 6.5. Pain Management Drugs
  • 6.5.1. Opioids
  • 6.5.2. Other Pain Management Drugs
  • 6.5.3. Steroids
• 6.6. Surgical Treatments
  • 6.6.1. Arthroscopic Surgery
  • 6.6.2. Joint Replacement Surgery
  • 6.6.3. Other Surgical Treatments

7. Canine Arthritis Market, by Route of Administration

• 7.1. Introduction
• 7.2. Injectable
• 7.3. Oral
• 7.4. Topical

8. Canine Arthritis Market, by End User

• 8.1. Introduction
• 8.2. Online Pharmacies
• 8.3. Retail Pharmacies
• 8.4. Veterinary Hospitals and Clinics

9. Canine Arthritis Market, by Therapy Type

• 9.1. Introduction
• 9.2. Drug Therapy
• 9.3. Physical Therapy
  • 9.3.1. Acupuncture
  • 9.3.2. Hydrotherapy
  • 9.3.3. Laser Therapy
  • 9.3.4. Other Physical Therapies
• 9.4. Surgical Therapy

10. Americas Canine Arthritis Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Canine Arthritis Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Canine Arthritis Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Bayer AG
• 2. Boehringer Ingelheim International GmbH
• 3. Ceva Sante Animale
• 4. Dechra Pharmaceuticals PLC
• 5. Elanco Animal Health Incorporated
• 6. Merck Animal Health
• 7. Nutramax Laboratories, Inc.
• 8. Vetoquinol S.A.
• 9. Virbac
• 10. Zoetis Inc.